During the past decade, Dr. Aldaoud - Dr. Schwarzer Forschungsgesellschaft mbH conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Dr. Aldaoud - Dr. Schwarzer Forschungsgesellschaft mbH" are "Chronic Myeloid Leukemia" (1 trials) and "Multiple Myeloma" (1 trials). Many other conditions were trialed in "Dr. Aldaoud - Dr. Schwarzer Forschungsgesellschaft mbH" in a lesser frequency.

Most popular intervention types in "Dr. Aldaoud - Dr. Schwarzer Forschungsgesellschaft mbH" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Lenalidomide" (1 trials), "Nilotinib" (1 trials), "Peginterferon α2b" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dr. Aldaoud - Dr. Schwarzer Forschungsgesellschaft mbH" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Dr. Aldaoud - Dr. Schwarzer Forschungsgesellschaft mbH". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Dr. Aldaoud - Dr. Schwarzer Forschungsgesellschaft mbH, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Dr. Aldaoud - Dr. Schwarzer Forschungsgesellschaft mbH, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".